ライフサイエンスコーパス: ciclosporin

1 cumbersome intravenous regimen required for ciclosporin.

2 ion phenytoin, calcium channel blockers, and ciclosporin.

3 l, or supportive treatment plus 12 months of ciclosporin.

4 itis were randomised to either infliximab or ciclosporin.

5 ned open-label tacrolimus or microemulsified ciclosporin.

6 cell carcinoma before and after first use of ciclosporin.

7 he approved dose, followed by omalizumab and ciclosporin.

8 ated with a higher acute rejection risk than ciclosporin.

9 eks and 6 weeks after the first infusion) or ciclosporin (2 mg/kg per day by continuous infusion for

10 ; p=0.0042); risk did not differ between the ciclosporin (29 [81%] of 36) and supportive treatment on

11 apremilast, azathioprine (AZA), baricitinib, ciclosporin A (CSA), corticosteroids, dupilumab, interfe

12 al systemic therapies, such as methotrexate, ciclosporin, acitretin, apremilast and deucravacitinib,

13 There was no significant difference between ciclosporin and infliximab in clinical effectiveness.

14 Two patients (one who received ciclosporin and one who received supportive therapy) wer

15 creased in patients assigned prednisone plus ciclosporin and prednisone plus methotrexate.

16 New data are available for drugs such as ciclosporin and thalidomide.

17 ession (generally antithymocyte globulin and ciclosporin), and high-dose cyclophosphamide.

18 ne, 32 (70%) of 46 allocated prednisone plus ciclosporin, and 33 (72%) of 46 administered prednisone

19 m received prednisolone and chlorambucil, 37 ciclosporin, and 38 supportive therapy alone.

20 one alone, 46 were allocated prednisone plus ciclosporin, and 46 were randomised prednisone plus meth

21 luding irinotecan (control), irinotecan plus ciclosporin, and irinotecan plus panitumumab (IrPan) gro

22 ond-line drugs, including alkylating agents, ciclosporin, and levamisole, may be effective for compli

23 Budesonide, ciclosporin, and rituximab have shown potential in modif

24 eatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline infusions.

25 Infliximab and ciclosporin are of similar efficacy in treating acute se

26 ; P < 0.01) and with tacrolimus-based versus ciclosporin-based immunosuppression (OR, 3.6; P < 0.01)

27 y over older agents such as methotrexate and ciclosporin, but long-term data are necessary.

28 3.3 months in those assigned prednisone plus ciclosporin, but was not observable in patients randomis

29 y transplant recipients (KTR) to maintaining ciclosporin (CSA) or to commencing TAC-based immunosuppr

30 immunosuppression than with microemulsified ciclosporin during the first year after liver transplant

31 three in the infliximab group vs none in the ciclosporin group).

32 cated to the infliximab group and 135 to the ciclosporin group.

33 the infliximab group vs 587.0 [226.2] in the ciclosporin group; mean adjusted difference 7.9 [95% CI

34 mab group vs 65 [48%] of 135 patients in the ciclosporin group; p=0.223); or mean time to colectomy (

35 nfliximab group vs 744 [638-850] days in the ciclosporin group; p=0.251).

36 portion of patients assigned prednisone plus ciclosporin had adverse events, affecting the skin and s

37 at of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatom

38 inical trial of panitumumab, irinotecan, and ciclosporin in colorectal cancer (PICCOLO) with with the

39 mous cell cancer of the skin is increased by ciclosporin in patients with psoriasis who have been exp

40 s to compare tacrolimus with microemulsified ciclosporin, in a regimen with standardised concomitant

41 Although ciclosporin-induced gingival overgrowth lesions exhibit

42 of squamous-cell carcinoma after any use of ciclosporin is close to that recorded for at least 200 P

43 ositive about treatment with infliximab than ciclosporin, mainly due to the cumbersome intravenous re

44 ents on tacrolimus and 40.2% for patients on ciclosporin microemulsion (p=0.0288).

45 tacrolimus group and 17 months (9-54) in the ciclosporin microemulsion group.

46 est that tacrolimus is more efficacious than ciclosporin microemulsion in the prevention of acute rej

47 rolimus/corticosteroids, n=93) with a triple ciclosporin microemulsion regimen (ciclosporin microemul

48 e 0.30 mg/kg for tacrolimus and 10 mg/kg for ciclosporin microemulsion.

49 a triple ciclosporin microemulsion regimen (ciclosporin microemulsion/corticosteroids/azathioprine,

50 or tacrolimus-treated patients and 70.4% for ciclosporin-microemulsion-treated patients (p<0.0001).

51 ombined treatment with prednisone and either ciclosporin or methotrexate was more effective than pred

52 ednisone alone or in combination with either ciclosporin or methotrexate.

53 Use of methotrexate, ciclosporin, or cyclophosphamide as first therapy improv

54 response in five patients taking nicorandil, ciclosporin, or isoflurane, which suggests that this dis

55 us 99 (32%) of 305 allocated microemulsified ciclosporin (relative risk 0.63 [95% CI 0.48-0.84], p=0.

56 infliximab vs ten in nine patients receiving ciclosporin); serious adverse events (21 in 16 patients

57 Ciclosporin should be avoided in this subset.

58 litis following treatment with infliximab or ciclosporin, surgery, or other medication.

59 of transplantation tolerance, drugs such as ciclosporin that interfere with activation-induced T-cel

60 side-effects from phenytoin, nifedipine, or ciclosporin therapy in approximately half of the people

61 ants in the PUVA follow-up study who were on ciclosporin to compare the frequency of squamous-cell ca

62 o recipient blood group A or B transfer, and ciclosporin treatment have been identified as risk facto

63 After ciclosporin use (average follow-up 6 years), 13 (46%) de

64 f tumours was seven times higher after first ciclosporin use than in the previous 5 years (incidence

65 he 5 years before first use, six of 28 (21%) ciclosporin users developed a total of 20 squamous cell

66 e risk of skin cancer in patients taking the ciclosporin who had been exposed to psoralen and ultravi